human
norovirus
inflict
signific
health
burden
societi
respons
approxim
million
infect
estim
death
worldwid
year
yet
despit
signific
research
effort
approv
vaccin
antivir
combat
pathogen
still
lack
safe
effect
antivir
avail
particularli
chronic
infect
immunocompromis
individu
prophylact
applic
protect
highm
re
rev
wileyonlinelibrarycomjournalm
risk
vulner
popul
outbreak
set
sinc
discoveri
human
noroviru
lack
cell
cultur
system
hinder
biolog
research
antivir
studi
mani
year
recent
breakthrough
cultur
human
noroviru
encourag
howev
develop
optim
novel
methodolog
requir
facilit
robust
replic
level
enabl
reliabl
serolog
replic
studi
well
advanc
antivir
develop
last
year
consider
progress
made
toward
develop
noroviru
antivir
invit
updat
review
review
focus
potenti
therapeut
report
sinc
examin
across
least
two
model
system
use
studi
human
noroviru
enzym
addit
place
emphasi
antivir
compound
defin
chemic
structur
includ
comprehens
outlin
directact
antivir
offer
discuss
hostmodul
compound
rapidli
expand
promis
area
antivir
research
although
high
preval
strain
reflect
part
world
lower
level
detect
australasia
europ
north
america
compar
asian
outbreak
period
human
noroviru
positivesens
singlestrand
rna
genom
kb
figur
karst
et
al
encod
protein
respect
major
capsid
protein
minor
capsid
protein
like
involv
capsid
assembl
genom
encapsid
protein
structur
compris
shell
protrud
p
domain
domain
enclos
viral
rna
antigen
variabl
p
domain
form
outer
surfac
also
involv
cell
attach
protein
express
baculoviru
selfassembl
viruslik
particl
vlp
vlp
antigen
structur
indistinguish
virion
produc
complet
viru
despit
clinic
signific
noroviru
infect
antivir
studi
hinder
recent
human
noroviru
could
success
propag
cell
cultur
recent
breakthrough
enabl
human
noroviru
cultur
b
cell
intestin
enteroid
repres
mileston
field
noroviru
biolog
howev
modest
replic
level
gener
new
system
log
increas
b
cell
f
g
u
r
e
schemat
human
noroviru
genom
noroviru
genom
positivesens
singlestrand
rna
genom
compris
three
orf
encod
nonstructur
protein
ntpase
vpg
proteas
rna
polymeras
structur
protein
log
increas
enteroid
mean
requir
optim
widespread
use
antivir
screen
develop
norwalk
viru
noroviru
replicon
system
use
assess
antivir
candid
human
viru
lieu
viral
cultur
system
figur
norwalk
replicon
consist
intact
genom
end
howev
disrupt
neomycin
gene
engin
region
subgenom
promot
preserv
express
intact
disrupt
selfrepl
stabli
express
cell
cell
line
norwalk
replicon
proven
use
tool
screen
potenti
antivir
compound
tabl
howev
replic
level
norwalk
replicon
rel
low
approxim
norwalk
rna
copi
per
cell
compar
replicon
system
hepat
c
viru
hcv
hcv
replicon
typic
yield
copi
per
cell
aa
eltahla
person
commun
use
identifi
mani
success
antivir
candid
moreov
amen
highthroughput
antivir
screen
review
horscroft
et
al
directli
led
mani
directact
antivir
daa
use
treat
hcv
infect
today
review
asselah
et
al
model
also
use
studi
antivir
efficaci
noroviru
figur
exampl
research
use
vitro
enzym
activ
assay
viral
polymeras
assay
proteas
assay
figur
screen
compound
antivir
activ
highthroughput
format
addit
xray
crystallographi
silico
model
use
examin
ligand
viral
protein
interact
elucid
antivir
mechan
f
g
u
r
e
current
method
identif
character
noroviru
antivir
flow
chart
depict
method
tool
avail
assess
effect
noroviru
antivir
panel
green
involv
combin
silico
vitro
method
panel
blue
yellow
repres
vitro
vivo
method
respect
purpl
panel
repres
clinic
test
human
patient
crfk
crandel
ree
felin
kidney
ic
half
maxim
inhibitori
concentr
qrtpcr
quantit
reversetranscript
polymeras
chain
reaction
rdrp
rnadepend
rna
polymeras
sar
structureact
relationship
tissu
cultur
infect
dose
color
figur
view
wileyonlinelibrarycom
replic
cycl
antivir
target
human
noroviru
schemat
complet
noroviru
replic
cycl
present
antivir
develop
noroviru
depict
turquois
circl
list
compound
repres
antivir
known
target
extens
list
antivir
describ
tabl
surrog
virus
within
calicivirida
famili
also
exploit
screen
inhibitori
activ
antivir
candid
across
sever
caliciviru
genera
figur
surrog
includ
murin
noroviru
mnv
noroviru
felin
caliciviru
fcv
vesiviru
porcin
sapoviru
sapoviru
rabbit
hemorrhag
diseas
viru
rhdv
lagoviru
tulan
viru
propos
genu
recoviru
mnv
particular
use
predomin
human
noroviru
surrog
classifi
within
genu
robustli
propag
cell
cultur
make
amen
viral
disinfect
steril
studi
addit
featur
make
mnv
desir
antivir
screen
includ
abil
manipul
revers
genet
whilst
vivo
studi
mice
mani
genet
background
straightforward
variou
anim
model
also
use
human
noroviru
challeng
studi
includ
nonhuman
primat
chimpanze
macaqu
marmoset
tamarin
addit
gnotobiot
miniatur
pig
gnotobiot
calv
also
use
well
knockout
human
mice
noroviru
infect
studi
howev
anim
model
deem
entir
suitabl
due
obviou
differ
clinic
diseas
gut
physiolog
microbiom
naiveti
noroviru
infect
compar
human
popul
low
genet
divers
laboratori
test
anim
everi
stage
human
noroviru
replic
cycl
repres
uniqu
target
antivir
develop
figur
howev
develop
antivir
therapi
target
viral
replic
requir
detail
understand
noroviru
biolog
viral
gene
function
much
still
elucid
overview
human
noroviru
lifecycl
specif
antivir
target
outlin
figur
stage
replic
cycl
antivir
target
includ
host
cell
attach
intern
genom
releas
viral
genom
replic
mediat
viral
rdrp
translat
genom
subgenom
templat
use
vpg
host
cell
machineri
viral
proteas
cleavag
viral
polyprotein
yield
matur
viral
protein
follow
assembl
packag
cell
egress
review
thorn
goodfellow
number
noroviru
antivir
report
publish
last
three
year
signific
recent
progress
field
warrant
updat
review
herein
includ
comprehens
overview
peerreview
studi
sinc
includ
antivir
candid
examin
least
two
differ
system
eg
viral
enzym
inhibit
assay
mnv
cell
cultur
note
plant
food
extract
antinoroviru
effect
omit
studi
activ
antivir
compound
unknown
review
focus
compound
defin
structur
outlin
tabl
includ
studi
use
recent
develop
human
noroviru
cell
cultur
system
b
cell
also
discuss
recent
identifi
broadspectrum
antivir
antinoroviru
activ
provid
comprehens
overview
hostmodul
compound
recent
novel
excit
area
within
noroviru
antivir
research
tabl
list
individu
antivir
compound
case
sever
similar
deriv
studi
list
potent
compound
group
repres
deriv
relev
citat
compound
index
clariti
throughout
manuscript
tabl
cell
attach
entri
featur
viral
replic
cycl
extens
investig
antivir
target
human
immunodefici
viru
hiv
dengu
viru
denv
hcv
amongst
other
design
compound
capabl
target
viral
entri
knowledg
viral
entri
receptor
usual
requir
recent
identifi
entri
receptor
mnv
howev
counterpart
receptor
human
noroviru
yet
discov
absenc
antivir
target
noroviru
entri
bia
toward
compound
prevent
noroviru
cellular
attach
wide
studi
attach
target
histoblood
group
antigen
hbga
hbga
complex
carbohydr
present
abundantli
surfac
mucos
epithelia
gastrointestin
tract
interact
surfac
domain
capsid
protein
thought
aid
viral
attach
perhap
even
entri
hbga
determin
host
cell
genet
review
tan
jiang
play
import
role
term
viru
host
interact
norovirus
initi
infect
one
studi
silico
screen
perform
drug
librari
million
compound
identifi
molecul
interact
strongli
hbga
prevent
noroviru
attach
potenti
hit
n
confirm
vitro
enzymelink
immunosorb
assay
elisa
base
human
noroviru
block
assay
reveal
compound
cyclopentaadimethyl
phenanthren
base
structur
n
display
potent
inhibit
ic
hbganoroviru
bind
potent
compound
seri
addit
xray
crystallographi
reveal
hmo
interact
directli
p
domain
capsid
thu
provid
clear
mechan
bind
inhibit
observ
despit
advanc
attach
inhibitor
test
vlp
less
common
genotyp
thu
effect
broader
spectrum
noroviru
strain
need
demonstr
passiv
immunotherapi
monoclon
antibodi
mab
nanobodi
nb
antivir
strategi
prevent
noroviru
attach
entri
would
particularli
use
immunocompromis
patient
crossgenotyp
activ
display
nb
illustr
molecul
potenti
overcom
narrow
antigen
spectrum
typic
display
convent
mab
howev
despit
find
mab
nb
studi
base
mostli
vlpbind
structur
analysi
bind
tabl
thu
effect
compound
noroviru
cell
cultur
vivo
need
explor
continu
develop
toward
clinic
applic
human
noroviru
antivir
target
rdrp
one
numer
preclin
candid
identifi
inhibit
activ
tabl
critic
viral
replic
rdrp
highli
attract
antivir
target
larg
netzler
et
al
lack
host
homolog
minim
chanc
offtarget
advers
effect
human
noroviru
polymeras
form
canon
rdrp
structur
resembl
close
right
hand
finger
palm
thumb
domain
figur
like
act
homodim
activ
state
rdrptarget
antivir
divid
two
major
class
nucleosid
analog
na
nonnucleosid
inhibitor
nni
na
inhibit
rna
synthesi
mimicri
incom
nucleosid
triphosph
ntp
upon
incorpor
subsequ
caus
chain
termin
less
commonli
increas
mutat
viral
genom
transcript
result
lethal
mutagenesi
also
known
error
catastroph
anoth
studi
report
similar
potenc
mnv
rna
level
reduct
potenc
norwalk
replicon
found
higher
differ
propos
due
either
vari
methodolog
studi
differ
drug
puriti
human
noroviru
bjab
cell
cultur
system
inhibit
human
noroviru
replic
ec
despit
variat
potenc
observ
vitro
system
collect
studi
illustr
polymeras
excel
antivir
target
crossgenogroup
inhibit
noroviru
replic
na
also
shown
promis
potenti
noroviru
antivir
mous
model
studi
knockout
mice
infect
mnv
treat
protect
mortal
diarrhea
reduc
noroviru
genom
titer
tissu
stool
log
reduct
compar
mocktreat
anim
addit
mnvinfect
mice
treat
high
dose
mgkgday
day
demonstr
reduc
transmiss
uninfect
sentinel
mice
cage
togeth
offer
prophylact
protect
day
attempt
improv
safeti
efficaci
therapi
sever
deriv
examin
antinoroviru
activ
exampl
one
studi
evalu
inhibitori
activ
hydroxycytidin
nhc
hbvhiv
na
lamivudin
replic
mnv
norwalk
replicon
potent
pangenotyp
activ
noroviru
reportedli
recruit
stage
phase
clinic
trial
evalu
safeti
toler
pharmacokinet
less
equal
healthi
adult
peerreview
public
avail
write
review
result
project
releas
later
nni
gener
exhibit
narrowspectrum
antivir
activ
bind
alloster
block
conform
rearrang
viral
polymeras
requir
form
activ
replic
complex
current
three
known
nni
bind
site
noroviru
rdrp
one
bind
pocket
within
ntp
access
path
locat
finger
thumb
domain
second
pocket
term
site
posit
charg
ntp
travers
channel
flexibl
amino
acid
side
chain
third
pocket
site
b
highli
conserv
alloster
bind
pocket
present
across
calicivirida
locat
within
thumb
region
figur
despit
promis
potenc
suramin
deriv
includ
ppnd
compound
demonstr
limit
bioavail
exhibit
poor
cell
permeabl
greatli
reduc
antivir
efficaci
viral
cultur
suramin
shown
inhibit
mnv
replic
cell
cultur
ec
larg
structur
low
cell
permeabl
meant
deliveri
requir
liposom
system
enter
cell
similarli
ppnd
found
much
less
potent
mnv
cell
cultur
demonstr
inhibit
mnv
replic
plaqu
assay
compar
inhibit
concentr
rdrp
assay
moreov
ppnd
elimin
enzym
inhibit
studi
due
nonspecif
offtarget
effect
therefor
like
unsuit
drug
candid
antinoroviru
develop
much
like
rdrp
noroviru
proteas
figur
repres
desir
antivir
target
sinc
play
essenti
role
viral
replic
cleavag
ns
polyprotein
necessari
product
viral
progeni
noroviru
proteas
inhibitor
pi
test
wide
rang
model
antivir
system
figur
repres
class
caliciviru
antivir
number
compound
tabl
although
potent
ts
mimic
far
less
studi
ts
inhibitor
repres
small
proport
compound
describ
tabl
first
ts
inhibitor
design
includ
seri
peptidyl
aldehyd
incorpor
glutamin
surrog
structur
take
advantag
prefer
noroviru
proteas
cleav
glutamineglycin
peptid
site
rupintrivir
effect
pi
across
multipl
genera
noroviru
genogroup
illustr
proteas
excel
antivir
candid
treatment
noroviru
infect
pitfal
use
daa
emerg
resist
mutat
undermin
effect
although
combin
therapi
proven
option
hiv
hcv
therapi
circumv
comparison
daa
antivir
target
host
gener
higher
barrier
resist
class
daa
howev
initi
studi
reveal
inhibit
mnv
mice
limit
small
intestin
due
poor
bioavail
address
poor
bioavail
librari
variant
develop
test
improv
antivir
efficaci
immunomodul
excel
therapeut
option
viral
infect
due
abil
induc
power
host
respons
intracellular
parasit
best
exampl
immunomodul
interferon
ifn
decad
studi
shown
type
ii
ifn
well
receptor
provid
protect
murin
human
noroviru
infect
howev
role
type
iii
ifn
noroviru
infect
potenti
noroviru
antivir
recent
explor
inhibit
uml
inhibit
norwalk
replicon
uml
vitamin
ainduc
chang
microflora
thought
mechan
respons
antivir
effect
lastli
nitazoxanid
ntz
cover
section
shown
promis
antivir
therapi
defin
mechan
activ
noroviru
yet
determin
recent
ntz
shown
potent
inhibit
fcv
replic
cell
cultur
ec
gi
noroviru
replicon
clinic
relev
concentr
later
shown
result
broad
antivir
respons
despit
observ
latter
studi
also
show
ntz
ineffect
mnv
suggest
antivir
investig
warrant
date
noroviru
antivir
vaccin
approv
medic
use
noroviru
antivir
candid
complet
clinic
trial
ntz
compound
origin
develop
current
fdaapprov
therapi
treat
giardia
crytosporidium
infect
ntz
demonstr
broadspectrum
antimicrobi
activ
rang
bacteri
protozoan
viral
infect
includ
inhibit
norwalk
replicon
ec
review
rossignol
phase
ii
random
doubleblind
trial
ntz
therapi
administ
patient
year
test
posit
rotaviru
noroviru
infect
treatment
result
signific
reduct
durat
gastroenter
symptom
noroviru
p
rotaviru
p
day
compar
placebo
addit
anecdot
studi
support
efficaci
ntz
treatment
noroviru
ntz
success
treat
one
immunosuppress
transplant
patient
infect
noroviru
experienc
consecut
day
gastroenter
symptom
four
day
commenc
ntz
treatment
complet
resolut
symptom
record
without
reduct
immunosuppress
drug
ntz
treatment
also
shown
resolv
diarrheal
symptom
clear
noroviru
stool
sampl
pediatr
patient
chronic
noroviru
follow
kidney
transplant
although
abovement
studi
suggest
ntz
promis
therapi
treatment
noroviru
infect
equal
amount
evid
reveal
ntz
ineffect
noroviru
netzler
et
al
infect
despit
contrari
evid
ntz
repres
therapeut
option
current
avail
apart
rbv
immunoglobulin
support
care
patient
persist
infect
human
noroviru
pervas
pathogen
creat
signific
social
econom
impact
caus
hundr
thousand
death
year
despit
intens
research
safe
effect
noroviru
antivir
none
yet
clinic
approv
major
candid
still
earli
stage
preclin
develop
review
outlin
recent
therapeut
candid
studi
provid
updat
overview
current
human
noroviru
antivir
develop
pipelin
optim
human
noroviru
cultur
enteroid
b
cell
system
offer
promis
time
robust
reliabl
cultur
method
develop
allow
greater
replic
level
improv
system
may
enhanc
antivir
studi
provid
stronger
platform
effect
noroviru
antivir
develop
landscap
antivir
develop
noroviru
chang
rapidli
develop
field
host
immunomodulatori
therapi
open
door
potenti
treatment
mani
viral
infect
promis
result
alreadi
publish
noroviru
moreov
recent
discoveri
report
highli
conserv
bind
pocket
critic
viral
enzym
noroviru
polymeras
could
allow
develop
broadspectrum
antivir
